About UCSF Search UCSF UCSF Medical Center

Jeffrey A. Bluestone, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
bluestone_jeffrey

Executive Vice Chancellor and Provost, UCSF
A.W. and Mary Margaret Clausen Distinguished Professorship in Metabolism and Endocrinology, UCSF

jbluestone@immunetolerance.org

Phone: (415) 514-1683 (voice)
Box 0540, UCSF
San Francisco, CA 94143-0542

View on UCSF Profiles


Education

Cook College, Rutgers University, B.S., 1974, Biology
Rutgers - State University, NJ, M.S., 1977, Microbiology
Cornell Graduate School of Medical Science (Sloan-Kettering Division), Ph.D., 1980, Immunology


Professional Experience

  • 1980-1982
    Anna Fuller Fund Postdoctoral Fellow, Immunology Branch, National Cancer Institute, NIH
  • 1982-1982
    Laboratory Leader, Senior Staff Fellow, Transplantation Biology Section, Immunology Branch, NCI, NIH
  • 1986-1982
    Senior Investigator, Transplantation Biology Section, Immunology Branch, NCI, NIH
  • 1987-1992
    Associate Professor, Ben May Institute, Dept. of Pathology and the Committee on Immunology, University of Chicago
  • 1991-2002
    Professor, Ben May Institute, Department of Pathology and the Committee on Immunology, University of Chicago and Chairman, Committee on Immunology
  • 1995-2002
    Director, Ben May Institute for Cancer Research
  • 1999-present
    Director, Juvenile Diabetes Center, University of Chicago and University of Minnesota
  • 1999-present
    Director, Immune Tolerance Network
  • 2000-present
    A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology; and Director, UCSF Diabetes Center, the Metabolic Research Unit and the Hormone Research Institute, UCSF

Honors & Awards

  • 1987-1982
    Gould Foundation Faculty Scholar
  • 1982
    American Cancer Society Faculty Scholar
  • 1992
    Guggenheim Senior Fellowship
  • 1992
    Fogarty Senior Research Fellowship
  • 1992
    Cornell Medical School - Distinguished Alumni Award
  • 2002
    Priscilla White Lecturer, Brigham & Women's Hospital, Joslin Diabetes Center
  • 2002
    Juvenile Diabetes Research Foundation Gerold & Kayla Grodsky Basic Science Award
  • 2002
    American Society for Transplantation Roche Distinguished Research Award
  • 2002
    Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award, Juvenile Diabetes Research Foundation
  • 2002
    Elected, American Academy of Arts and Sciences

Selected Publications

  1. Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone JA. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014 Oct 15; 6(258):258ra142.
    View on PubMed
  2. Folias AE, Penaranda C, Su AL, Bluestone JA, Hebrok M. Aberrant Innate Immune Activation following Tissue Injury Impairs Pancreatic Regeneration. PLoS One. 2014; 9(7):e102125.
    View on PubMed
  3. Stumpf M, Zhou X, Chikuma S, Bluestone JA. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol. 2014 Jun; 44(6):1737-46.
    View on PubMed
  4. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-Hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H. Pathogenic conversion of Foxp3(+) T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014 Jan; 20(1):62-8.
    View on PubMed
  5. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-Driven Activation Induces Instability of Regulatory T Cells during an Inflammatory Autoimmune Response. Immunity. 2013 Nov 14; 39(5):949-62.
    View on PubMed
  6. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013 Nov; 3(11).
    View on PubMed
  7. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA, Trotta E, Szot GL, Liu W, Lares A, Lee K, Laing A, Lechler RI, Riley JL, Bluestone JA, Lombardi G, Tang Q. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant. 2013 Nov; 13(11):3010-20.
    View on PubMed
  8. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):306-16.
    View on PubMed
  9. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol. 2013; 4:232.
    View on PubMed
  10. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19.
    View on PubMed
  11. Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA. Production of a-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol. 2013 Jul; 11(7):e1001610.
    View on PubMed
  12. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605.
    View on PubMed
  13. Bour-Jordan H, Thompson HL, Giampaolo JR, Davini D, Rosenthal W, Bluestone JA. Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. J Autoimmun. 2013 Sep; 45:58-67.
    View on PubMed
  14. Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 2013 Aug; 62(8):2870-8.
    View on PubMed
  15. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74.
    View on PubMed
  16. Baumjohann D, Kageyama R, Clingan JM, Morar MM, Patel S, de Kouchkovsky D, Bannard O, Bluestone JA, Matloubian M, Ansel KM, Jeker LT. The microRNA cluster miR-17~92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol. 2013 Aug; 14(8):840-8.
    View on PubMed
  17. Jeker LT, Zhou X, Blelloch R, Bluestone JA. DGCR8-mediated production of canonical microRNAs is critical for regulatory T cell function and stability. PLoS One. 2013; 8(5):e66282.
    View on PubMed
  18. Jeker LT, Bluestone JA. MicroRNA regulation of T-cell differentiation and function. Immunol Rev. 2013 May; 253(1):65-81.
    View on PubMed
  19. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013 Apr 3; 5(179):179ps7.
    View on PubMed
  20. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Apr; 13(4):243-56.
    View on PubMed

Go to UCSF Profiles, powered by CTSI